FY2028 EPS Estimates for Personalis Cut by HC Wainwright

Personalis, Inc. (NASDAQ:PSNL) – Investment analysts at HC Wainwright decreased their FY2028 earnings per share estimates for shares of Personalis in a report released on Thursday, November 7th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $0.40 per share for the year, down from their previous estimate of $0.53. HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Personalis’ current full-year earnings is ($1.15) per share.

A number of other equities analysts have also issued reports on PSNL. Needham & Company LLC reaffirmed a “buy” rating and set a $7.25 target price on shares of Personalis in a research report on Thursday. BTIG Research boosted their target price on shares of Personalis from $5.50 to $7.00 and gave the stock a “buy” rating in a research report on Friday, August 16th.

Personalis Trading Up 5.3 %

Shares of PSNL stock opened at $4.55 on Friday. Personalis has a 1 year low of $0.89 and a 1 year high of $7.20. The firm’s fifty day simple moving average is $5.13 and its 200 day simple moving average is $3.35. The firm has a market capitalization of $241.51 million, a P/E ratio of -2.71 and a beta of 1.94.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.10. Personalis had a negative net margin of 104.52% and a negative return on equity of 72.35%. The business had revenue of $22.58 million for the quarter, compared to the consensus estimate of $19.81 million. During the same quarter last year, the company posted ($0.50) earnings per share.

Institutional Investors Weigh In On Personalis

Several institutional investors and hedge funds have recently bought and sold shares of PSNL. ARK Investment Management LLC increased its holdings in Personalis by 11.4% in the 3rd quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock valued at $38,120,000 after buying an additional 723,637 shares during the period. Jacobs Levy Equity Management Inc. increased its holdings in Personalis by 144.7% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 821,657 shares of the company’s stock valued at $1,224,000 after buying an additional 485,822 shares during the period. Acadian Asset Management LLC increased its holdings in Personalis by 90.7% in the 1st quarter. Acadian Asset Management LLC now owns 991,828 shares of the company’s stock valued at $1,476,000 after buying an additional 471,646 shares during the period. Semanteon Capital Management LP bought a new stake in Personalis in the 3rd quarter valued at $375,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Personalis by 98.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 108,788 shares of the company’s stock valued at $585,000 after purchasing an additional 53,965 shares in the last quarter. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.